Listing of european cities

Característiques urbanes de les ciutats europees amb una població igual o superior als 100.000 habitants, ordenades per ordre alfabètic.Características urbanas de las ciudades europeas con una población igual o superior a los 100.000 habitantes, ordenadas por orden alfabético.Urban characteristics of the European cities with an equal population or superior to the 100,000 inhabitants, alphabetically ordered

La perspectiva urbana

En aquest article es presenten els objectius de l'estudi, i al mateix temps s'ofereix una visió de conjunt de la realitat urbana i metropolitana europea

La perspectiva urbana

En aquest article es presenten els objectius de l'estudi, i al mateix temps s'ofereix una visió de conjunt de la realitat urbana i metropolitana europea.In this article the objectives of the study are introduced, and at the same time a joint vision of the European urban and metropolitan reality is offered.En este artículo se presentan los objectivos del estudio, y al mismo tiempo se ofrece una visión de conjunto de la realidad urbana y metropolitana europea

Datos de las grandes metrópolis europeas

Fitxes de cada una de les aglomeracions metropolitanes estudiades, en què s'aporta informació numèrica i cartogràfica de la seva estructura (ciutats que la componen, grandària i densitat). Com a novetat en aquesta edició, també s'aporta informació sobre la forma de govern metropolità de cadascuna d'elles.Statistical and catographical information (cities that make it up, sixe and density) and on the metropolitan government of each agglomeration studied.Fichas de cada una de les aglomeracions metropolitanes estudiadas, con información numérica y cartográfica de su estructura (ciudades que la componen, tamaño y densidad). Como a novedad en esta edición, también se aporta información sobre la forma de gobierno metropolitano de cada una de ellas

Metodologia

En aquest article s'expliciten els procediments metodològics que s'han utilitzat per determinar els 10.630 municipis urbans i les 104 aglomeracions metropolitanes europees. També s'hi fa una comparació amb els resultats amb l'edició de 2002 i amb els d'altres estudis de referència

Dades de les grans metròpolis europees

Fitxes de cada una de les aglomeracions metropolitanes estudiades, en què s'aporta informació numèrica i cartogràfica de la seva estructura (ciutats que la componen, grandària i densitat). Com a novetat en aquesta edició, també s'aporta informació sobre la forma de govern metropolità de cadascuna d'elles

L'Europa urbana i els governs metropolitans

En aquest capítol s'exposen les competències de les institucions de govern de les diferents aglomeracions metropolitanes, així com les raons de la seva complexitat

Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when = 50 years and symptomatic for <= 7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with <= 5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)